Summary:
- Otsuka Pharmaceutical has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of centanafadine in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults.
- Centanafadine is a novel compound that works by increasing the levels of certain neurotransmitters in the brain, which can help improve focus, concentration, and impulse control in individuals with ADHD.
- If approved by the FDA, centanafadine could provide a new treatment option for individuals with ADHD, potentially offering improved efficacy and a favorable safety profile compared to existing medications.